{
  "_metadata": {
    "version": "2.1",
    "ticker": "EWTX",
    "company_name": "Edgewise Therapeutics, Inc.",
    "data_source": "ewtx_jpm_2026",
    "extraction_date": "2026-02-11"
  },
  "ticker": "EWTX",
  "name": "Edgewise Therapeutics, Inc.",
  "company": {
    "name": "Edgewise Therapeutics, Inc.",
    "ticker": "EWTX",
    "exchange": "NASDAQ",
    "headquarters": "Boulder, Colorado",
    "website": "https://www.edgewisetx.com",
    "one_liner": "Edgewise is a muscle disease biopharmaceutical company developing first-in-class therapies for muscular dystrophies and serious cardiac conditions, led by sevasemten — an oral fast skeletal myosin inhibitor in a pivotal trial for Becker muscular dystrophy with no FDA-approved therapies."
  },
  "investment_thesis_summary": {
    "core_thesis": "Edgewise is poised for a transformative 2026 with the GRAND CANYON pivotal readout for sevasemten in Becker muscular dystrophy (Q4 2026), targeting the first-ever FDA-approved therapy in a disease with zero approved treatments. If successful, NDA submission is planned for H1 2027 with commercial launch potential that year. The company also has a diversified cardiac pipeline (EDG-7500 in HCM, EDG-15400 in heart failure) providing multiple shots on goal.",
    "key_value_drivers": [
      "GRAND CANYON pivotal readout in Becker (Q4 2026) — potential first-ever approved therapy in this disease",
      "NDA submission planned H1 2027 with commercial infrastructure already being built",
      "EDG-7500 CIRRUS-HCM 12-week data in H1 2026 with Phase 3 start targeted H2 2026",
      "Strong balance sheet (~$563M cash as of Q3 2025, plus $200M from April 2025 follow-on)"
    ]
  },
  "investment_analysis": {
    "bull_case": [
      "Sevasemten targets a disease (Becker) with zero FDA-approved therapies and clear regulatory path (FDA Type C meeting confirmed GRAND CANYON as single adequate study for registration)",
      "GRAND CANYON is highly powered (N=175) for NSAA primary endpoint over 18 months; MESA OLE shows sustained stabilization after 3 years of treatment",
      "CANYON Phase 2 met primary endpoint (CK reduction) and showed NSAA stabilization vs placebo at 12 months — 0.8 point improvement from baseline in MESA rollover",
      "Commercial infrastructure being built for potential 2027 launch; Orphan Drug and Fast Track designations secured for both Becker and Duchenne",
      "EDG-7500 HCM data showing improvements in NT-proBNP, KCCQ, NYHA and LVOT gradient; Phase 3 targeted H2 2026",
      "Cash position of ~$563M (Q3 2025) plus $200M follow-on provides substantial runway",
      "Pipeline optionality: Duchenne Phase 3 design planned H2 2026 (10mg dose selected); EDG-15400 in heart failure entering Phase 2"
    ],
    "bear_case": [
      "GRAND CANYON is a binary event — entire thesis depends on showing statistically significant NSAA difference vs placebo at 18 months",
      "FDA deemed CANYON data alone insufficient for accelerated approval, requiring the larger GRAND CANYON study",
      "Becker is a rare disease (~3,500-5,000 US patients) which may limit peak sales potential",
      "Pre-revenue company with Q3 2025 net loss of $40.7M and no approved products",
      "EDG-7500 had one AF event in Part D (deemed not drug-related) — cardiac safety monitoring is ongoing concern for sarcomere modulators",
      "No commercial revenue or approved products; company substantially dependent on sevasemten and EDG-7500 success"
    ],
    "key_debates": [
      {
        "question": "Will GRAND CANYON show statistically significant NSAA improvement vs placebo at 18 months?",
        "bull_view": "Trial is highly powered with N=175; CANYON Phase 2 showed NSAA stabilization at 12 months; MESA OLE shows 3-year durability with NSAA diverging from natural history; FDA supportive of endpoint and trial design",
        "bear_view": "Becker natural history is variable; NSAA stabilization (not improvement) may be hard to distinguish from placebo in a larger trial; FDA rejected accelerated approval based on CANYON alone",
        "what_resolves_it": "GRAND CANYON top-line data Q4 2026"
      },
      {
        "question": "Can EDG-7500 differentiate in HCM and succeed in both obstructive and nonobstructive forms?",
        "bull_view": "Part D interim safety favorable; improvements across NT-proBNP, KCCQ, NYHA; no clinically meaningful LVEF declines; potential for both oHCM and nHCM (nHCM has no approved therapies)",
        "bear_view": "One AF event reported; competitive HCM landscape (mavacamten, aficamten); full Part D efficacy data pending",
        "what_resolves_it": "CIRRUS-HCM Part D 12-week data H1 2026 (specifically 2Q 2026)"
      }
    ]
  },
  "pipeline_summary": {
    "total_programs": 4,
    "clinical_stage": 3,
    "programs": [
      {
        "asset": "Sevasemten",
        "target": "Fast skeletal myosin",
        "stage": "Pivotal (GRAND CANYON) / Phase 2 (Duchenne)",
        "indications": "Becker muscular dystrophy, Duchenne muscular dystrophy",
        "ownership": "Wholly-owned",
        "next_catalyst": "GRAND CANYON top-line data — Q4 2026",
        "source": {"id": "ewtx_jpm_2026", "slide": null, "verified": false}
      },
      {
        "asset": "EDG-7500",
        "target": "Cardiac sarcomere",
        "stage": "Phase 2 (CIRRUS-HCM)",
        "indications": "Hypertrophic cardiomyopathy (obstructive and nonobstructive)",
        "ownership": "Wholly-owned",
        "next_catalyst": "CIRRUS-HCM Part D 12-week data — H1 2026",
        "source": {"id": "ewtx_jpm_2026", "slide": null, "verified": false}
      },
      {
        "asset": "EDG-15400",
        "target": "Cardiac sarcomere",
        "stage": "Phase 1",
        "indications": "Heart failure (HFpEF)",
        "ownership": "Wholly-owned",
        "next_catalyst": "Phase 1 SAD/MAD data — H1 2026; Phase 2 in HFpEF results H1 2027",
        "source": {"id": "ewtx_jpm_2026", "slide": null, "verified": false}
      },
      {
        "asset": "EDG-003",
        "target": "Not disclosed",
        "stage": "Preclinical / undisclosed",
        "indications": null,
        "ownership": null,
        "next_catalyst": null,
        "source": {"id": "ewtx_jpm_2026", "slide": null, "verified": false}
      }
    ]
  },
  "platform": {
    "name": "Muscle Physiology Platform",
    "description": "Edgewise's deep expertise in muscle physiology is driving a new generation of novel therapeutics across both skeletal and cardiac muscle diseases, leveraging sarcomere biology and myosin modulation."
  },
  "financials": {
    "cash_position": "$563.3 million (as of September 30, 2025) plus $200M net proceeds from April 2025 follow-on",
    "cash_runway": null,
    "market_cap": "~$3.1B (as of Feb 3, 2026)",
    "enterprise_value": null,
    "revenue": "Pre-revenue (no products approved for commercial sale)",
    "r_and_d_expense": "$37.5 million (Q3 2025)",
    "net_loss": "$40.7 million (Q3 2025)",
    "shares_outstanding": "105,761,949 (as of Sep 30, 2025)",
    "source": {"id": "ewtx_q3_2025", "slide": null, "verified": false}
  },
  "catalysts": [
    { "asset": "EDG-7500", "event": "CIRRUS-HCM Part D 12-week data (oHCM and nHCM)", "timing": "H1 2026 (2Q 2026)", "importance": "critical", "what_to_watch": "Full efficacy data in both obstructive and nonobstructive HCM; cardiac safety including AF/flutter monitoring" },
    { "asset": "EDG-15400", "event": "Phase 1 SAD/MAD data in healthy adults", "timing": "H1 2026", "importance": "medium", "what_to_watch": "Safety, PK, and dose selection for Phase 2 in HFpEF" },
    { "asset": "Sevasemten", "event": "Duchenne Phase 3 design finalization and FDA meeting", "timing": "H2 2026", "importance": "high", "what_to_watch": "Phase 3 trial design incorporating 10mg dose from LYNX/FOX Phase 2" },
    { "asset": "EDG-7500", "event": "Phase 3 initiation in oHCM and nHCM", "timing": "H2 2026", "importance": "high", "what_to_watch": "Trial design, dose selection, and competitive positioning vs mavacamten/aficamten" },
    { "asset": "Sevasemten", "event": "GRAND CANYON pivotal top-line data in Becker", "timing": "Q4 2026", "importance": "critical", "what_to_watch": "Statistically significant NSAA difference vs placebo at 18 months — binary event for the company" },
    { "asset": "Sevasemten", "event": "NDA submission to FDA for Becker", "timing": "H1 2027", "importance": "critical", "what_to_watch": "Traditional approval pathway based on NSAA; potential first-ever approved therapy in Becker" },
    { "asset": "EDG-15400", "event": "Phase 2 results in HFpEF", "timing": "H1 2027", "importance": "high", "what_to_watch": "Efficacy and safety in heart failure with preserved ejection fraction" }
  ]
}
